Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00619112 · ClinicalTrials.gov registry record · Phase 2
Temozolomide in Treating Patients With Recurrent High-Grade Glioma
A Phase 2 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT00619112 is a Phase 2 study that has completed, run by University of California, San Francisco. The registered enrollment target is 60 participants.
The verdict
NCT00619112, a Phase 2 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well temozolomide works in treating patients with recurrent high-grade glioma.
Interventions
- DRUG temozolomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2007-10 |
| Est. Completion | 2012-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00619112
The ClinicalTrials.gov registry entry for NCT00619112 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which temozolomide is the first listed.
NCT00619112 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00619112 about?
NCT00619112 is a clinical study titled "Temozolomide in Treating Patients With Recurrent High-Grade Glioma". RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well temozolomide works in treating patients with recurrent high-grade g...
What is the current status of trial NCT00619112?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2007-10. Estimated completion is 2012-09.
What interventions are being tested in trial NCT00619112?
The interventions under investigation include: temozolomide (DRUG).
Who is sponsoring clinical trial NCT00619112?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.